Epilepsy is a physical state which starts in the brain. Epilepsy is characterized by recurring unprovoked seizures. Sometimes seizures are related to a provisional state, such as the exposure to drugs, the withdrawal of certain drugs, or the abnormal levels of sodium or glucose in blood. There are many various types of seizures. The kind of seizure that a person has to count on which part and which quantity of brain is affected by the electric disturbance which produces seizures. Some seizures are idiopathic, which means that the cause cannot be identified. Such seizures usually start between ages 5 and 20, but they can occur at any age.

Epilepsy is a state of the nervous system which affects 2.5 million americans. Many people develop the epilepsy like children or years of adolescence. Others develop it later in the life. For some with the epilepsy (in particular kids), the seizures become finally less frequent or disappear completely. People can have strange feelings and emotions or behave curiously. They can have spasms violent one of muscle or lose the conscience. The epilepsy has possible damage of brain of much of causes and the abnormal development of brain. The principal damage or the lack of oxygen during the birth can damage the significant electric system in the brain.

Other causes include tumours of brain, conditions genetic, the wire poisoning, of the problems being studied of the brain before birth, and the infections like meningitis or the encéphalite. Sometimes the seizures stop without treatment. Many people take antiepileptic drugs to control seizures. Antiepileptic drugs function beside reducing the abnormal setting with fire of the cortical neurons. These drugs can change the activity of the neuro-transmitters responsible for the seizures or to change the manner the ions run in and out of the neurons. The neurosurgical operations for the epilepsy can be palliative, reducing the frequency.

When the drug fails, the surgery can be performed to treat the epilepsy. There are various types of surgery which were employed. The temporal surgery of lobe is carried out to remove fabric of brain where the access epileptic starts. This type of surgery often removes a part of the cortex of the lobe, hippocampus and amygdala temporal. The corpus callosotomy is cut to divide the goods and left cerebral hemispheres. This process is made to prevent the diffusion of the seizure on a side of the brain to the other. The surgery of Hemispherectomy east remove cerebral.

While about 80 percent of people with epilepsy gain significant relief from drug therapy, the remaining 20 percent have seizures that cannot be controlled by epilepsy medications. Many of these people have a particular type of epilepsy called partial epilepsy. A new study shows that people with partial epilepsy often have seizures controlled by medications for years before their seizures become drug-resistant. The study also found that periods when seizures stopped for a year or more are common in these patients.

“This study opens the door for early identification of patients who will later develop drug-resistant partial epilepsy, which may in turn allow us to identify ways of preventing some forms of epilepsy from ever becoming drug-resistant,” says lead author Anne T. Berg, Ph.D., of Northern Illinois University in DeKalb, who is part of a large multicenter team directed by Susan Spencer, M.D., at Yale University in New Haven, Connecticut. The study was funded by the National Institute of Neurological Disorders and Stroke (NINDS) and appears in the January 28, 2003, issue of Neurology. 1

In the new study, researchers looked at patients who had surgery for drug-resistant partial epilepsy to identify factors that predict when seizures will become intractable, or no longer controllable with medications. They also studied the incidence of previous seizure-free periods in this group. Partial epilepsy results from abnormal neuronal activity that originates in a single part of the brain, usually in one of the temporal lobes.

Epilepsy is a disorder in which clusters of nerve cells, or neurons, in the brain display patterns of abnormal activity. This activity can cause a variety of symptoms, including convulsions. Physicians have described dozens of different kinds of epilepsy. “Epilepsy is not a single disorder - like cancer, it’s a multitude of disorders with varying symptoms, prognoses, and implications for specific treatment,” says Dr. Berg. Partial epilepsy accounts for about 40 to 50 percent of childhood epilepsy and 90 percent of adult-onset epilepsy, she adds. Other types of epilepsy result from abnormal neuronal activity in many parts of the brain.

In this study, researchers looked at 333 patients who had undergone surgery for partial seizures and who were part of a larger ongoing study to examine the outcomes of epilepsy surgery. Most of these patients had temporal lobe epilepsy, or TLE. The researchers examined medical records and conducted structured interviews with these patients to determine the duration, frequency, and types of seizures the patients experienced. They found that patients’ average age when they had their first seizure was 14.6 years, while the average age at which they underwent surgery was 36.7 years. The 282 patients for whom historical data were available had been diagnosed with epilepsy an average of 9 years before their epilepsy became intractable. Intractable epilepsy in this study was defined as a failure of two medications to control seizures.

The researchers also asked about previous periods when the patients had been seizure-free. About one quarter of the patients said they had had seizure-free periods of a year or more. Twenty-four patients (8.5 percent) had seizure-free periods of 5 years or more. A seizure-free period of 1 year or longer was most common in people who were younger than 5 when they were diagnosed. The results show that a history of seizure-free periods is common in people who later develop intractable seizures.

The study identified several factors that were related to the amount of time before seizures became intractable. These factors included age of onset, type of surgery the patients received, history of febrile (fever-related) seizures, and atrophy of the hippocampus, the region of the brain that is affected in TLE. Of these factors, age of onset had the strongest relationship with the amount of time until intractability, Dr. Berg says. In patients whose seizures began before age 5, it took an average of 15 years for seizures to become intractable. In patients whose epilepsy began during their 30s and 40s, however, seizures tended to become intractable immediately or within only a few years.

“Consistent with other reports, many individuals in our study did indeed have epilepsy that became intractable within a short time after its initial onset. What is startling, however, is the large number of patients who experienced prolonged periods of seizure control before their seizures became intractable,” Dr. Berg says. Based on the 15-year average time it took for early-onset seizures to become intractable, Dr. Berg says that studies of epilepsy prognosis need to proceed for at least that amount of time in order to identify patients who might develop intractable seizures late in the course of the disorder.

The results of this study pertain only to partial epilepsy, primarily TLE, and cannot and should not be generalized to other forms of epilepsy, Dr. Berg notes.

“These data give us some clues, but they only begin to scratch the surface. We need careful, prospective long-term studies in order to accurately understand the long-term prognosis of partial epilepsy,” says Dr. Berg. She and her colleagues are now conducting additional studies to determine which patients develop intractable seizures.

Suffering from sleep deprivation can have a lot of adverse side effects, and sleeplessness is even more dangerous if the person has epilepsy. Epilepsy is a common chronic neurological disorder and is associated with the seizures sufferers acquire involuntarily. The seizures are symptoms of an excessive, abnormal, or synchronous neuronal activity in the brain. It is estimated that fifty million people all over the world has epilepsy or has experienced epilepsy at one point in their lives.

Although not all epilepsies are permanent, there is no cure for it. Medications can help control epileptic shocks but epilepsy itself either lasts for certain stages of childhood or it could very well be a lifelong affliction. Also, epilepsy in itself is not a single syndrome. There are numerous precipitating factors for its occurrence, and it all culminates as an abnormal activity in the brain which causes the shock.

Although most epilepsy shocks happen spontaneously or at random, there can be triggers for epilepsy. Shock during drug and alcohol withdrawal is not considered epilepsy. The triggers can be normal day to day activities. These are called normal provocants, and it can include reading, hot water on the head, and hyperventilation. Flashing or flickering lights is a special type of reflex epilepsy called photosensitive epilepsy. Though popularly known as an epileptic trigger, only two to fourteen percent of epilepsy sufferers are affected by it. Environmental factors that can lead to an epileptic shock or seizures can be sleeping, or hypnogogia (which is the transition between being unconscious state of sleeping and waking state). Menstruation, constipation, stress and anxiety and alcohol can be other epileptic triggers.

Moreover, sleep deprivation, as most doctors and researchers have found out, is also linked with epilepsy. Epilepsy and sleep deprivation can work both ways: epilepsy can make it difficult for sufferers to go to sleep at night, and sleeplessness in turn, can lead to an epileptic shock. Epilepsy is not limited during a person’s waking state: there can be full or partial seizures during sleeping. People who are epileptic are also more likely to develop sleeping disorders compared to the rest. Insomnia is not the only adverse effect of epilepsy. Epileptics are also more likely to develop obstructive sleep apnea (restriction in the airways, causing pauses in breathing while asleep), restless leg syndrome, among others.

Medications to control the seizures can also be the cause why epileptics have a harder time sleeping. It has been found that these medicines can cut their sleeping time or cause erratic sleeping habits. What is worse is that since being deprived of sleep can cause more seizures, and epilepsy (and medications) can cause sleep deprivation, epileptics can be caught in a vicious cycle. It is just like connecting the dots: since sleep deprivation can affect the brain, and epilepsy shock is caused by episodic abnormal electrical activity in the brain, the link between epilepsy and sleep deprivation is a dangerous combination.

Dealing with both epilepsy and sleep deprivation is a serious matter. One has to consult a doctor, and epileptics might need to change their daily habits, their environment, and so on. It takes a great deal of effort, but with the help of doctors and professionals, it can be managed.

Epilepsy is a physical condition that occurs when there is a sudden, brief change in how the brain works. When brain cells are not working properly, a person’s consciousness, movement, or actions may be altered for a short time. These physical changes are called epileptic seizures. Therefore, epilepsy is sometimes called a seizure disorder. Epilepsy affects people in all nations and of all races.

What Causes Epilepsy

Any condition that keeps blood or oxygen from getting to the brain (e.g. hardening of the arteries)

Alzheimer’s disease or other diseases that change the brain’s structure

Dozens of genetic syndromes representing a variety of seizure patterns may account for the different forms epilepsy.

A genetic cause has been identified for at least some cases of juvenile myoclonic epilepsy, which represents 10% of all epilepsy cases. (Such research and other studies have pointed to the GABA signaling system as an important player in many cases of epilepsy.)

Symptoms of Epilepsy

The severity of symptoms can vary greatly, from simple staring spells to loss of consciousness and violent convulsions. For many patients, the event is the same thing over and over, while some people have many different types of seizures that cause different symptoms each time. The type of seizure a person has depends on a variety of many things, such as the part of the brain affected and the underlying cause of the seizure.

Experiencing changes in the way things look, smell, feel, taste, or sound.

Experiencing an intense feeling of déjà vu (a feeling that these events have happened before).

Epileptic seizures often happen without warning, although some people may have an aura at the beginning of a seizure. A seizure ends when the abnormal electrical activity in the brain stops and brain activity begins to return to normal. Seizures may be either partial or generalized.

How is epilepsy diagnosed?

First, a detailed history is needed. A physical and neurologic exam are performed by your veterinarian, a panel of laboratory tests are run, and sometimes x-rays (radiographs) are taken. If a cause of the seizure can not be identified, the condition is diagnosed as idiopathic or primary epilepsy. There is no test to diagnose epilepsy per se, our tests simply rule out other causes of seizures.

How Can You Treat Epilepsy

The goal of epilepsy treatment is to treat, and prevent, seizures.

In some cases, seizures can occur because of the presence of a substance, infection, or other condition. These can be stopped by treating the fever, the poisoning, low blood sugar or the infection, if this is discovered to be the cause of the seizures.

Some medications can be taken daily in order to prevent seizures altogether or reduce the frequency of their occurrence. These are termed “anticonvulsant” or “antiepileptic” drugs (sometimes AEDs). All such drugs have side effects which are idiosyncratic and others which are dose-dependent; it is not possible to predict who will suffer from side effects or at what dose the side effects will appear.

Because of serious side effects, felbamate is not recommended as first-line therapy in the treatment of seizures. The manufacturer recommends its use only in patients who do not adequately respond to alternative therapy and whose epilepsy is so severe that the substantial risks of aplastic anemia and hepatic failure are deemed acceptable.8 Its use requires that the physician be thoroughly familiar with the drug. The manufacturer recommends that written consent be obtained before initiation of therapy.

Monotherapy in adults should begin with 1,200 mg of felbamate daily, given in divided doses every six to eight hours. Daily dosages should increase by 600 mg every two weeks to a total daily dosage of 2,400 to 3,600 mg. As adjunctive therapy, treatment should begin at 1,200 mg daily, given in divided doses every six to eight hours. If the patient is taking phenytoin, valproic acid or carbamazepine, a 20 to 35 percent reduction in the dosage of these drugs is recommended during felbamate therapy. Levels of antiepileptic drugs should be followed as the dosage of felbamate is increased to 2,400 to 3,600 mg daily.

The beginning dosage of felbamate in children aged two to 14 years with Lennox-Gastaut syndrome is 15 mg per kg, given in three to four divided doses. Dosages of other antiepileptic drugs should be reduced by 20 percent, with further reductions based on side effects or drug levels. The daily dosage of felbamate should increase by 15 mg per kg weekly, to a maximum of 45 mg per kg.

The most common side effects include anorexia, vomiting, insomnia, nausea, headache, dizziness and somnolence.10 One overdose has been reported. The patient improved with supportive care. Clinical effects of overdose included epigastric distress and tachycardia.

After initial marketing of the drug, two very serious toxic effects appeared: aplastic anemia and hepatic failure. The risk of aplastic anemia in patients taking felbamate is 100 times greater than it is in the general population. One in every 3,600 to 5,000 patients taking felbamate will have aplastic anemia. The fatality rate of this complication approaches 30 percent. Aplastic anemia may not manifest itself until several months after initiation of treatment, and patients may remain at risk for an undetermined amount of time after treatment is discontinued. The syndrome may begin without warning and may not be reliably detected by routine testing. Patients taking felbamate should remain alert for signs of infection, bleeding and easy bruising, or symptoms of anemia such as fatigue or weakness.

Hepatotoxicity leading to hepatic failure is estimated to occur in one in every 24,000 to 34,000 patients taking felbamate. Felbamate should not be used in patients with a history of hepatic dysfunction.

The need for monitoring drug levels has not been established. However, baseline laboratory testing should include a complete blood count, platelet count and reticulocyte count, as well as determination of liver enzyme levels. Hematologic evaluations should be performed frequently during treatment and after discontinuation of treatment. Liver enzyme levels should be determined every one to two weeks, and felbamate therapy should be discontinued if the aspartate aminotransferase, alanine aminotransferase or bilirubin levels increase above baseline.

Felbamate (Felbatol) is approved for adjunctive or monotherapy in adults with partial seizures with or without secondary generalization. It is also approved for use in children with Lennox-Gastaut syndrome, a childhood disorder with multiple seizure types, slow spike-wave electroencephalograms, mental retardation and resistance to standard therapy with antiepileptic drugs. The mechanism of action is not known, but it has been shown to have weak inhibitory effects on GABA receptor binding sites. Because of serious potential toxicity, felbamate should be reserved for rare, compassionate use by physicians experienced in treating patients with epilepsy that is difficult to control.
Felbamate is absorbed well orally with bioavailability greater than 90 percent. Absorption is not affected by food. Metabolism occurs by the hepatic cytochrome P450 system, but 40 to 50 percent of the drug is excreted unchanged in the urine. Felbamate affects the steady-state concentrations of other antiepileptic drugs that depend on hepatic metabolism. The addition of felbamate increases the levels of phenytoin and valproic acid and decreases the levels of carbamazepine while concurrently increasing its epoxide concentration. The addition of phenytoin or carbamazepine reduces felbamate levels by 40 percent. Because felbamate is only 25 percent protein bound, minimal binding effects occur with protein-bound drugs.

Felbamate is also considered a category C medication during pregnancy. Because it is found in breast milk, breast feeding is not recommended for patients taking felbamate. Pediatric use is approved only for adjunctive therapy in children with Lennox-Gastaut syndrome.

Lamotrigine binds to melanin-containing tissues such as the iris of the eye, but the long-term effects of this binding and accumulation are unknown. Use in pregnant patients is recommended only if the benefit outweighs the potential risks. Lamotrigine is classified as a category C medication during pregnancy. A registry of pregnant patients using lamotrigine is maintained by the manufacturer. The drug is found in breast milk; thus nursing is not recommended during treatment. Lamotrigine is contraindicated for use in patients under the age of 16 because of the increased risk of developing a life-threatening rash.

Overdoses of up to 10 times the usual daily dosage have been reported. Recovery occurred with supportive care. There is no specific antidote.

The starting dosage in patients who are not taking valproic acid should be 50 mg daily for two weeks, increasing to 50 mg twice daily for an additional two weeks, and then increasing by 100 mg per day weekly to a maintenance level of 150 to 250 mg twice daily.

In patients who are taking valproic acid plus other anticonvulsant drugs that induce hepatic enzymes, the initial starting dosage should be reduced to 25 mg every other day for two weeks, then increased to 25 mg daily for two weeks. The dosage may be increased by 25 to 50 mg daily every one to two weeks up to a maximum of 75 mg twice daily.

A macular, papular or erythematous rash may develop in approximately 10 percent of patients during the first four to six weeks of treatment with lamotrigine. Although the rash often resolves with continued use, it may sometimes be indicative of serious systemic involvement. The occurrence of a rash or systemic symptoms such as fever or lymphadenopathy necessitates prompt discontinuation of the drug and medical evaluation. One in every 1,000 adults treated with lamotrigine develops severe, life-threatening rashes such as Stevens-Johnson syndrome, toxic epidermal necrolysis and angioedema with fever, facial swelling and lymphadenopathy. This risk is increased more than threefold with co-administration of valproic acid.

In children, the risk of developing a life-threatening rash is one in 50. Hence, use of lamotrigine is not indicated in children under 16 years of age. The risk of rash may increase if lamotrigine is given at higher than recommended dosages or if initial dosing is accelerated over recommendations provided by the manufacturer.

Because of the potential for severe life-threatening skin reactions, the FDA has required that the manufacturer of lamotrigine publish a special warning on the label of this product.

There is a risk of withdrawal seizures if therapy is discontinued abruptly; thus, gradual tapering of the medication over a two-week period is recommended. Caution is advised in patients with conditions that could affect elimination such as renal or hepatic impairment or the co-administration of valproic acid. Dosage reduction is mandated in patients with significant renal impairment.

Lamotrigine (Lamictal) is included in the phenyltriazine class. It is used as adjunctive therapy or monotherapy in adults with partial seizures with or without secondary generalization. The mechanism of action is unknown. Lamotrigine has been shown to act at voltage-sensitive sodium channels, stabilizing neural membranes and inhibiting the release of excitatory neural transmitters.
Lamotrigine is well absorbed orally, with up to 98 percent bioavailability. Absorption is not affected by food. Approximately 55 percent of the drug is protein bound; therefore, clinical interaction with other protein-bound drugs is unlikely. Ninety percent of the drug undergoes glucuronic acid conjugation in the liver, with the conjugate and the remaining 10 percent of unmetabolized drug excreted in the urine. Clearance is markedly increased by the co-administration of other antiepileptic drugs that induce hepatic enzymes. These include carbamazepine (Tegretol), phenobarbital, phenytoin (Dilantin) and primidone (Mysoline). The half-life of lamotrigine may be reduced by about 50 percent with concomitant use of one or more of these medications. However, when combined with valproic acid, its elimination is decreased, and its half-life may be more than doubled.

Lamotrigine does not impair cognition and has a relatively broad spectrum of activity against multiple types of seizures. Three multicenter clinical studies have demonstrated its efficacy as adjunctive therapy in adults with refractory partial seizures.
The only contraindication to lamotrigine is hypersensitivity to the drug. The need for monitoring drug levels has not been established. The most frequently encountered adverse reactions include dizziness, ataxia, somnolence, headache, blurred vision, nausea, vomiting and rash. Up to 10 percent of patients discontinue lamotrigine therapy because of side effects. One case of acute hepatic failure has been reported. Because lamotrigine depresses the central nervous system, patients who are taking it should be cautioned about driving or operating complex machinery.